NYSEAMERICAN:APHB Ampliphi Biosciences (APHB) Stock Price, News & Analysis $3.12 +0.05 (+1.67%) As of 10/3/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Ampliphi Biosciences Stock (NYSEAMERICAN:APHB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ampliphi Biosciences alerts:Sign Up Key Stats Today's Range$3.09▼$3.1350-Day Range$2.41▼$3.1252-Week Range$0.15▼$1.37Volume5,666 shsAverage Volume842,200 shsMarket Capitalization$104.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ampliphi Biosciences, Inc. is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company’s core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials. The company’s lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures. XF-73 has demonstrated the potential to significantly reduce surgical site infections by targeting nasal carriage of S. aureus, including methicillin‐resistant strains. Beyond XF-73, Ampliphi is expanding its pipeline through its proprietary drug conjugate platform, which seeks to create novel antibacterial compounds active against a broad spectrum of Gram‐negative and Gram‐positive pathogens. Founded on a scientific foundation of antimicrobial innovation, Ampliphi Biosciences emerged following the strategic divestiture of earlier antifungal programs to a major pharmaceutical partner. The company operates primarily in North America and is preparing to extend its global footprint through strategic collaborations and licensing agreements. Ampliphi is supported by a leadership team with deep expertise in infectious disease drug development, manufacturing, and regulatory affairs, positioning the company to advance its candidates toward commercialization and address critical unmet needs in patient care.AI Generated. May Contain Errors. Read More Receive APHB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampliphi Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APHB Stock News HeadlinesAsian Pac Holdings Bhd (APHB)September 28, 2024 | investing.comPacific Biosciences Stock (NASDAQ:PACB), Analyst Ratings, Price Targets, PredictionsOctober 24, 2023 | benzinga.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed. | StockEarnings (Ad)Akston Biosciences Strengthens Board with Addition of John T. PrestonJanuary 25, 2023 | finance.yahoo.comSelecta Biosciences Stock (NASDAQ:SELB), Quotes and News SummaryJanuary 5, 2023 | benzinga.comAPHB: Case Study on AB-PA01 Presented at ISHLT Annual MeetingOctober 26, 2021 | finance.yahoo.comSee More Headlines APHB Stock Analysis - Frequently Asked Questions How have APHB shares performed this year? Ampliphi Biosciences' stock was trading at $1.9490 at the beginning of the year. Since then, APHB shares have increased by 60.1% and is now trading at $3.12. How were Ampliphi Biosciences' earnings last quarter? Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07. How do I buy shares of Ampliphi Biosciences? Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ampliphi Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Protalix BioTherapeutics (PLX), Athersys (ATHX) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings3/25/2019Today10/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:APHB Previous SymbolAMEX:APHB CIK921114 Webwww.ampliphibio.com Phone+1-804-8272524FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares33,469,000Free FloatN/AMarket Cap$104.42 million OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSEAMERICAN:APHB) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampliphi Biosciences Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampliphi Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.